Get the Stockscreener App
24.81
3.61%
-0.93
After Hours:
24.91
0.10
+0.40%
Viking Therapeutics Inc stock is traded at $24.81, with a volume of 4.04M.
It is down -3.61% in the last 24 hours and down -37.76% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$25.74
Open:
$25.88
24h Volume:
4.04M
Relative Volume:
0.70
Market Cap:
$2.79B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-26.68
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-8.04%
1M Performance:
-37.76%
6M Performance:
-16.04%
1Y Performance:
-60.50%
1-Day Range:
$24.80
$25.89
1-Week Range:
$24.80
$26.84
52-Week Range:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
24.81 | 2.91B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
This Under-the-Radar Healthcare Stock Could Soar in 2026 - AOL.com
This Under-the-Radar Healthcare Stock Could Soar in 2026 - The Motley Fool
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback - Mitrade
Alliancebernstein L.P. Decreases Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Comerica Bank Sells 20,767 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Curi RMB Capital LLC Grows Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX) Valuation: Are Investors Paying Too Much for Future Growth? - simplywall.st
Where Does VKTX Stock Stand After the Obesity Pill Setback? - Zacks Investment Research
Viking Therapeutics (VKTX): Reassessing Valuation After Clinical Trial Setback and Weak Earnings - Yahoo Finance
Eventide Asset Management LLC Sells 187,290 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
EFG Asset Management North America Corp. Sells 22,649 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Cinctive Capital Management LP Buys 42,344 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Granahan Investment Management LLC Raises Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735 - MSN
Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate - MSN
Insider Trends: What’s the analyst consensus on Viking Therapeutics Inc2025 Top Decliners & High Accuracy Investment Entry Signals - Lancaster City Council
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? - MSN
Viking Therapeutics (VKTX) Gets a Buy from Piper Sandler - The Globe and Mail
Published on: 2025-09-09 13:05:54 - Lancaster City Council
Viking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout Rate - MSN
Is Summit Therapeutics a Buy, Sell, or Hold Now? - AOL.com
Why Is Viking Therapeutics Stock (VKTX) Down 40% Today? - MSN
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Viking Therapeutics at Morgan Stanley Conference: Expanding Obesity Treatment Horizons - Investing.com
Viking Therapeutics Inc. Outperforms Peers on Volume MetricsJuly 2025 WrapUp & Accurate Intraday Trade Tips - beatles.ru
Viking Therapeutics Shares Under Pressure Amid Losses - TipRanks
Jim Cramer Recommends Eli Lilly Over Viking Therapeutics - Insider Monkey
Magnetar Financial LLC Decreases Stake in Viking Therapeutics, Inc. $VKTX - MarketBeat
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time. - MSN
ADAR1 Capital Management LLC Buys 50,113 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Can Viking Therapeutics Inc. lead its sector in growthVolume Spike & Verified Technical Trade Signals - beatles.ru
Trend analysis for Viking Therapeutics Inc. this week2025 Major Catalysts & Target Return Focused Picks - Newser
When is the best time to exit Viking Therapeutics Inc.2025 Volatility Report & Stock Portfolio Risk Control - Newser
Can swing trading help recover from Viking Therapeutics Inc. lossesM&A Rumor & Daily Stock Trend Reports - Newser
Can Viking Therapeutics Inc. withstand a market correctionQuarterly Earnings Summary & Weekly Hot Stock Watchlists - خودرو بانک
Is Viking Therapeutics Inc. stock heavily shortedEarnings Beat & Daily Price Action Insights - خودرو بانک
Can Viking Therapeutics Inc. outperform in the next rallyQuarterly Investment Review & AI Based Buy and Sell Signals - خودرو بانک
Landscape Capital Management L.L.C. Buys Shares of 10,003 Viking Therapeutics, Inc. $VKTX - MarketBeat
Apis Capital Advisors LLC Increases Stock Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
Why Viking Therapeutics Inc. is moving today2025 Market Outlook & High Conviction Buy Zone Alerts - Newser
Will Viking Therapeutics Inc. benefit from macro trends2025 Risk Factors & Expert Approved Trade Ideas - Newser
Market reaction to Viking Therapeutics Inc.’s recent newsMarket Volume Report & Detailed Earnings Play Strategies - Newser
Is Viking Therapeutics Inc. exposed to political riskLayoff News & Fast Exit and Entry Trade Guides - خودرو بانک
Institutional scanner results for Viking Therapeutics Inc.Market Risk Report & Reliable Trade Execution Plans - Newser
Jim Cramer Expects Palantir To Reach New All-Time High - Benzinga
Forecasting Viking Therapeutics Inc. price range with options dataJuly 2025 Opening Moves & Technical Pattern Alert System - Newser
Exit strategy if you’re trapped in Viking Therapeutics Inc.Swing Trade & Community Trade Idea Sharing - Newser
Is Viking Therapeutics Inc. stock entering bullish territory2025 Valuation Update & AI Powered Market Trend Analysis - Newser
Down 34%, Should You Buy the Dip on Viking Therapeutics? - AOL.com
How Viking and Axsome Stocks Could Double by 2030 - NAI500
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):